Healthcare Investing, Chapter 10 - Investing in Pharmaceuticals
Here is a chapter from Health Care Investing, which couples strategies for making money on the future growth of the health-care industry with insightful coverage of the people and events that have shaped it. You will find valuable information about the issues health care professionals face today; examinations of patterns, policies, and future predictions in the market; and practical approaches to investing in pharma, biotech, and managed care.
What people are saying - Write a review
We haven't found any reviews in the usual places.
acquisitions advertising analyst assets available at SSRN big pharmaceutical companies Biotech biotechnology branded company Branded drugs business models capital changes clinical trials companies need company’s ability compounds conservative assumptions considerations include cost create shareholder value developing new drugs different diseases Divestitures drug class Drug Development Drug Discovery drug prices Economics Working Paper factors fail FTC Bureau guidelines higher impact important infrastructure innovation Intellectual property investment Investors need isomers label large pharmaceutical companies larger companies lead Mergers Metz off-label outcome overall patent expirations patients peak sales pharma pharmaceutical industry pharmaceutical manufacturers Pharmacogenomics physicians potential preclinical prescribing patterns Prescription Drug projects re-creation value reduce reform package regulators regulatory reimbursement require returns risk sales force sales process sector serendipity significant small pharmaceutical companies smaller pharmaceutical strategies success target selection therapeutic class therapies treatment paradigm types ultimate vaccines value proposition Vioxx